The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial with tamoxifen in combination with vorinostat and pembrolizumab in estrogen receptor (+) hormone therapy resistant metastatic breast cancer patients (NCT02395627).
 
Manuela Terranova Barberio
No Relationships to Disclose
 
Scott Thomas
No Relationships to Disclose
 
Amy Jo Chien
No Relationships to Disclose
 
Hope S. Rugo
Honoraria - Genomic Health
Speakers' Bureau - Genomic Health
Research Funding - Celsion (Inst); Celsion (Inst); Eisai (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Mylan; Nektar; Novartis; OBI Pharma; Roche/Genentech
 
Michelle E. Melisko
Stock and Other Ownership Interests - Merrimack (I)
Honoraria - Agendia; Genentech; Genentech (I); Nektar; Pfizer (I)
Consulting or Advisory Role - Genentech (I)
Speakers' Bureau - Agendia; Genentech (I); Pfizer (I)
Research Funding - Celldex (Inst); Galena Biopharma (Inst); Genentech (Inst); Lilly (Inst); Puma Biotechnology (Inst)
Patents, Royalties, Other Intellectual Property - Multiple patents related to immunoliposomal drugs being studied and potentially brought to market by Merrimack (I)
 
Austin Nicholas Angelidakis
No Relationships to Disclose
 
Nela Pawlowska
No Relationships to Disclose
 
Travis Deal
No Relationships to Disclose
 
Pamela N. Munster
Stock and Other Ownership Interests - OncoSec (I)
Honoraria - Amgen (I); Prometheus (I); Threshold Pharmaceuticals
Consulting or Advisory Role - HUYA Bioscience International
Research Funding - Andes Biotechnologies (Inst); Biomarin (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Intellikine (Inst); Merck (Inst); Merrimack (Inst); Nektar (Inst); Novartis (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); oncosec (Inst); Pfizer (Inst); Piramal Life Science (Inst); Plexxikon (Inst); Sanofi (Inst)